ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Stock Information for ADC Therapeutics SA
Loading
Please wait while we load your information from QuoteMedia.